The Medicines Company (MDCO) Analysts See $-1.48 EPS; Last Week NBT Bancorp Inc. (NBTB) Analysts

February 15, 2018 - By David Stenberg

Among 6 analysts covering NBT Bancorp Inc (NASDAQ:NBTB), 0 have Buy rating, 0 Sell and 6 Hold. Therefore 0 are positive. NBT Bancorp Inc had 19 analyst reports since August 3, 2015 according to SRatingsIntel. Piper Jaffray downgraded the shares of NBTB in report on Wednesday, November 16 to “Underweight” rating. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Tuesday, October 3 report. The rating was upgraded by PiperJaffray to “Neutral” on Thursday, June 8. The company was maintained on Wednesday, February 7 by Piper Jaffray. The stock of NBT Bancorp Inc. (NASDAQ:NBTB) has “Hold” rating given on Wednesday, January 24 by Boenning & Scattergood. Keefe Bruyette & Woods maintained NBT Bancorp Inc. (NASDAQ:NBTB) on Tuesday, July 25 with “Hold” rating. The rating was maintained by Sandler O’Neill on Wednesday, January 3 with “Hold”. The firm earned “Underweight” rating on Wednesday, November 16 by PiperJaffray. The rating was initiated by Piper Jaffray on Thursday, January 7 with “Neutral”. Boenning & Scattergood maintained it with “Sell” rating and $3500 target in Tuesday, July 25 report. See NBT Bancorp Inc. (NASDAQ:NBTB) latest ratings:

07/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $38.0 Maintain
05/02/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $40.5 Maintain
24/01/2018 Broker: Boenning & Scattergood Rating: Hold Maintain
03/01/2018 Broker: Sandler O’Neill Rating: Hold New Target: $38.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $44.5 Maintain
23/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $35.0 Maintain
24/10/2017 Broker: Boenning & Scattergood Rating: Hold Maintain
03/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $38.0 Maintain

Analysts expect The Medicines Company (NASDAQ:MDCO) to report $-1.48 EPS on February, 27.They anticipate $0.19 EPS change or 14.73% from last quarter’s $-1.29 EPS. After having $-0.42 EPS previously, The Medicines Company’s analysts see 252.38% EPS growth. The stock increased 0.53% or $0.17 during the last trading session, reaching $32.09. About 1.20M shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since February 15, 2017 and is uptrending. It has by 0.00% the S&P500.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company has market cap of $2.32 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It currently has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 35 analyst reports since August 28, 2015 according to SRatingsIntel. Leerink Swann maintained it with “Buy” rating and $53 target in Monday, August 31 report. Chardan Capital Markets maintained it with “Buy” rating and $65 target in Monday, March 21 report. The firm has “Buy” rating by Cowen & Co given on Tuesday, August 29. The stock has “Outperform” rating by RBC Capital Markets on Monday, November 16. Oppenheimer upgraded the stock to “Buy” rating in Wednesday, November 29 report. The firm has “Hold” rating by Oppenheimer given on Thursday, August 10. As per Monday, June 26, the company rating was maintained by Jefferies. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Wednesday, November 4 by Chardan Capital Markets. The firm has “Hold” rating by Oppenheimer given on Wednesday, July 12. The firm has “Market Perform” rating given on Monday, August 31 by Oppenheimer.

Since December 7, 2017, it had 1 insider buy, and 1 sale for $1.60 million activity. The insider ESHELMAN FREDRIC N bought $5.31 million. On Friday, December 15 MEANWELL CLIVE sold $3.71 million worth of The Medicines Company (NASDAQ:MDCO) or 136,250 shares.

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.44, from 1.22 in 2017Q2. It dropped, as 32 investors sold The Medicines Company shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. Cim Inv Mangement holds 0.08% or 6,157 shares in its portfolio. State Of Alaska Department Of Revenue reported 12,629 shares. State Board Of Administration Of Florida Retirement Sys stated it has 0% in The Medicines Company (NASDAQ:MDCO). Piedmont Inv Llc reported 13,923 shares. Stevens Cap L P accumulated 0.01% or 8,477 shares. Alphaone Investment Serv Ltd has 580 shares for 0.01% of their portfolio. Quantbot Ltd Partnership reported 4,622 shares. Putnam Investments Lc reported 1.50M shares or 0.13% of all its holdings. Venbio Select Advisor Limited Liability Corp holds 1.72M shares or 4.94% of its portfolio. Corvex Mngmt L P has 2.41 million shares. Cibc Asset Mngmt Incorporated reported 6,296 shares. Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in The Medicines Company (NASDAQ:MDCO). Jpmorgan Chase And stated it has 0% of its portfolio in The Medicines Company (NASDAQ:MDCO). Granahan Inv Ma holds 0.1% in The Medicines Company (NASDAQ:MDCO) or 32,948 shares. Rock Springs Mngmt L P reported 690,000 shares or 1.18% of all its holdings.

The stock increased 2.08% or $0.74 during the last trading session, reaching $36.35. About 122,921 shares traded. NBT Bancorp Inc. (NASDAQ:NBTB) has risen 27.32% since February 15, 2017 and is uptrending. It has outperformed by 10.62% the S&P500.

NBT Bancorp Inc. operates as the bank holding firm for NBT Bank, National Association that provides commercial banking and financial services to individuals, firms, and municipalities. The company has market cap of $1.58 billion. The companyÂ’s deposit products include demand deposit accounts, savings accounts, negotiable order of withdrawal accounts, money market deposit accounts, and certificate of deposit accounts. It has a 19.44 P/E ratio. The Company’s loan portfolio comprises commercial loans, commercial real estate loans, agricultural and agricultural real estate loans, and business banking loans; consumer loans, such as indirect, home equity, and direct loans; and residential real estate mortgages, as well as real estate construction and development loans.

Since October 25, 2017, it had 0 insider purchases, and 4 insider sales for $2.15 million activity. $964,500 worth of NBT Bancorp Inc. (NASDAQ:NBTB) was sold by Robinson V Daniel II. CHEWENS MICHAEL J sold $160,938 worth of stock or 4,190 shares. Wadsworth Robert A also sold $60,452 worth of NBT Bancorp Inc. (NASDAQ:NBTB) on Thursday, January 25.

Investors sentiment increased to 1.26 in Q3 2017. Its up 0.05, from 1.21 in 2017Q2. It improved, as 5 investors sold NBT Bancorp Inc. shares while 37 reduced holdings. 17 funds opened positions while 36 raised stakes. 21.42 million shares or 0.37% more from 21.34 million shares in 2017Q2 were reported. Laurion Capital Mgmt Limited Partnership reported 9,500 shares. Public Sector Pension Investment Board holds 0% in NBT Bancorp Inc. (NASDAQ:NBTB) or 27,455 shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in NBT Bancorp Inc. (NASDAQ:NBTB) for 23,853 shares. New York-based Allsquare Wealth Mngmt Limited Liability has invested 0.07% in NBT Bancorp Inc. (NASDAQ:NBTB). Piedmont Inv Advisors Ltd Liability has 9,478 shares. Northern Trust invested 0.01% of its portfolio in NBT Bancorp Inc. (NASDAQ:NBTB). Great West Life Assurance Co Can invested in 0.01% or 59,500 shares. Comerica Bankshares invested in 45,891 shares or 0.01% of the stock. Peoples Fincl Services stated it has 140,025 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% of its portfolio in NBT Bancorp Inc. (NASDAQ:NBTB). Commonwealth Equity has 0.02% invested in NBT Bancorp Inc. (NASDAQ:NBTB) for 96,412 shares. Vanguard Group Inc Inc accumulated 4.06M shares or 0.01% of the stock. Prudential Financial owns 0% invested in NBT Bancorp Inc. (NASDAQ:NBTB) for 74,786 shares. Natixis reported 6,277 shares. State Of Alaska Department Of Revenue owns 8,603 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: